Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib
Fuminori Takahashi(Tokyo University of Science), Shyamala Maheswaran(Massachusetts General Hospital), Naokazu Chiba(Center for Cancer Research), Tetsu Hayashida(Center for Cancer Research), Elena F. Brachtel(Harvard University), Elena J. Edelman(Harvard University), Shivapriya Ramaswamy(Dana-Farber Cancer Institute), Takashi Shimada(Kyowa Kirin (Japan)), Ken Tajima(Harvard University), Mirei Takahashi(Harvard University), Hitomi Moriyama(Harvard University)
Cited by 66